Medical Condition News

RSS

System to help identify patients at high risk of developing delirium

A specialist in caring for elderly patients, Turner-Hubbard is a geriatric nurse practitioner trained to quickly spot the sudden changes in mental status that signal the onset of the sudden, severe confusion known as delirium. She knows the hospital “triggers” that can bring on fluctuations in behavior: blood loss during surgery, anesthesia, pain medications and anti-anxiety drugs, infections, dehydration, IV lines and catheters, as well as being immobilized for an extended period of time.

19 Nov 2009

NeuroRehabilitation: A one-stop resource for persons with neurodisabilities

IOS Press announces the November 2009 publication of a special issue of NeuroRehabilitation: An International Journal devoted to residential design for persons with neurodisability.

19 Nov 2009

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

Colorectal carcinoma is one of the most common cancers in the world. Approximately one in four of these patients have metastases at diagnosis, liver being the most common site involved. Although historically it was considered that liver metastases meant a very poor prognosis, today, due to improved systemic therapy, many patients will be candidates for local hepatic treatments such as surgery or less aggressive radiofrequency ablation.

19 Nov 2009

AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.

19 Nov 2009

New report finds positive association between phthalate exposure and ADHD symptoms

Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

19 Nov 2009

Possible new approach to slow the progression of cognitive decline in Down's syndrome

A study by neuroscientist William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine, and colleagues at Stanford University Medical School has demonstrated a possible new approach to slowing the inevitable progression of cognitive decline found in Down's syndrome.

19 Nov 2009

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA.

19 Nov 2009

USP releases new CRMs for carbamazepine, phenytoin, and theophylline

To help bring greater certainty to the measurement of medication levels in a patient's bloodstream for three drugs with narrow therapeutic ranges, the U.S. Pharmacopeial Convention (USP) is releasing new certified reference materials (CRMs).

19 Nov 2009

Reduction of serum bilirubin, the hallmark of successful biliary drainage

Biliary drainage is performed as a palliative treatment of hilar cholangiocarcinoma. The reduction of serum bilirubin is usually the hallmark of successful biliary drainage. However, some patients may have persistent jaundice or scanty bile output after biliary drainage.

19 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

First nationwide comprehensive obesity registry for bariatrics

RemedyMD (www.RemedyMD.com), the leading provider of disease registry software, today announced the first nationwide comprehensive obesity registry for bariatrics. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

UAB expert recommends research and evidence to interpret new mammography guidelines

The public may have problems this week sorting through news articles about a government task force's opposition to routine mammograms for women under 50 and articles about breast cancer survivors touting the benefits of early mammograms. But to properly interpret the news, the public must learn to balance the research with the anecdotal evidence says University of Alabama at Birmingham (UAB) Associate Professor of English Cynthia Ryan, Ph.D.

19 Nov 2009

Final results from ImmuPharma's Phase IIb trial of LUPUZOR

ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.

19 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

Joint project focuses on finding ways to prevent dementia, including Alzheimer's disease

Every two years, 2,000 senior Group Health patients check in with the Adult Changes in Thought (ACT) study. The joint project between Group Health Research Institute and the University of Washington (UW) focuses on finding ways to delay or prevent dementia, including Alzheimer's disease, and declines in memory and thinking.

19 Nov 2009

Queen’s University Belfast to study individualized radiotherapy treatment for breast cancer

Individualised radiotherapy treatment based on a person’s genetic make up could soon become a reality, according to Breast Cancer Campaign.

19 Nov 2009

New radical approach to test chemo drugs for potential toxic effects

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects.

19 Nov 2009

Researchers develop new device with nano-sized features to grab cancer cells

Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.

19 Nov 2009

New mathematical model may hasten drug development for Parkinson's Disease

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.

19 Nov 2009

Medical Condition News

System to help identify patients at high risk of developing delirium

NeuroRehabilitation: A one-stop resource for persons with neurodisabilities

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

New report finds positive association between phthalate exposure and ADHD symptoms

Possible new approach to slow the progression of cognitive decline in Down's syndrome

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

USP releases new CRMs for carbamazepine, phenytoin, and theophylline

Reduction of serum bilirubin, the hallmark of successful biliary drainage

BIMR wins a GO grant from the National Institute of Mental Health

First nationwide comprehensive obesity registry for bariatrics

New biomarkers can predict patients' response to certain drugs

UAB expert recommends research and evidence to interpret new mammography guidelines

Final results from ImmuPharma's Phase IIb trial of LUPUZOR

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Joint project focuses on finding ways to prevent dementia, including Alzheimer's disease

Queen’s University Belfast to study individualized radiotherapy treatment for breast cancer

New radical approach to test chemo drugs for potential toxic effects

Researchers develop new device with nano-sized features to grab cancer cells

New mathematical model may hasten drug development for Parkinson's Disease

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News